Daniel Passeri - Sep 24, 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Stock symbol: CUE
Transactions as of: Sep 24, 2021
Transactions value $: $50,051
Form type: 4
Date filed: 9/27/2021, 04:30 PM
Next filing: Oct 8, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CUE	Common Stock	Purchase	$50.1K	+3.4K	+6.54%	$14.72	55.4K	Sep 24, 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.63 to $14.749, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.63 to $14.749, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.